Text/HTML
Text/HTML
If you are a registered user please log in to see more postings.
 

The AAO Weblog covers accounting issues and current events as they relate the practice of investment analysis.

 
 
Oct 25

Written by: Jack Ciesielski
10/25/2006 6:41 AM 

There's a long restatement period facing Integrated Silicon Solution, Inc. and Valeant Pharmaceutical International: as far back as 1997 financial statements.

Today, Monster Worldwide joins the ranks of long-term restaters. In their 8-K filing of current financial statements, they also provide an update on their option investigation:

"The Company is still conducting its accounting analysis and has not yet determined definitively the impact of these differences on the Company's historical financial statements. However, the Company expects that it will restate its previously filed financial statements for the years 1997 through 2005... the Company's board of directors has concluded that the Company's previously issued financial statements and other historical financial information and related disclosures relating to periods through December 31, 2005 contained in the Company's filings with the Securities and Exchange Commission (the “SEC”), including applicable reports of its independent registered public accounting firm and press releases, should not be relied upon."


It's way too soon to call this a trend. The approach makes sense though, from the standpoint of giving shareholders information about the economics of pay within these firms during those long-past years. While there may be nothing material in 2006, as Monster notes, the roots of these problems might have an effect on years to which 2006 might be compared. When the facts are all displayed for shareholders, the revised history of all these firms is going to be interesting.

Tags:
 

Unexplored Obligations: Other Postretirement Benefits

Defined benefit pension plans take center stage in the pantheon of investors’ fears when it comes to worrying about liquidity effects or earnings distortions. Yet they rarely consider the cash demands and earnings distortions resulting from other postretirement benefit plans.

Since they’ve been required to measure - and display - a figure expressing the value of the promises made for providing employee health care benefits, managers have dealt vigorously with the obligations. Their growth has been held in check while pension obligations have grown ever higher. Yet even as they’ve become more controlled, other postretirement benefit plans are worth investor attention. As the benefit plans become less fearsome, the accounting principles involved have helped an increasing number of companies recognize phantom earnings - negative benefit costs - even while they’re putting cash into benefit payments under these plans. It’s better to be alert to such a trend early: firms may not always bring it to the attention of investors.

A recent edition of The Analyst’s Accounting Observer looks at the problematic reporting, with an eye focused on the "phantom income" results shown by 42 companies having negative OPEB costs. While the report is available only to paid subscribers, a condensed version is available for free upon request. To receive it, send an e-mail to Brenda Rappold at brappold@accountingobserver.com, with “OPEB Costs” in the subject line.


For information about subscribing to The Analyst’s Accounting Observer, click here.